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Next-generation DNA sequencing has revolutionized
the field of genetics and genomics, providing
researchers with the tools to efficiently identify novel
rare and low frequency risk variants, which was not
practical with previously available methodologies.
These methods allow for the sequence capture of a
specific locus or small genetic region all the way up
to the entire six billion base pairs of the diploid
human genome.
Rheumatic diseases are a huge burden on the US
population, affecting more than 46 million Americans.
Those afflicted suffer from one or more of the more
than 100 diseases characterized by inflammation and
loss of function, mainly of the joints, tendons,
ligaments, bones, and muscles. While genetics studies
of many of these diseases (for example, systemic lupus
erythematosus, rheumatoid arthritis, and inflammatory
bowel disease) have had major successes in defining
their genetic architecture, causal alleles and rare
variants have still been elusive. This review describes
the current high-throughput DNA sequencing
methodologies commercially available and their
application to rheumatic diseases in both case–control
as well as family-based studies.excess of a single sample’s needs for adequate coverage.
To effectively utilize this resource and decrease costs, re-Introduction
Within the past 6 years, the advent of high-throughput
sequencing methodologies has provided researchers and
clinicians with an extremely powerful tool for querying
large amounts of the genetic landscape within not only
single individuals but also cohorts of many individuals.
Often dubbed ‘next-generation sequencing’ (NGS) or
‘second generation sequencing’, these methodologies rely* Correspondence: Patrick-Gaffney@omrf.org
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unless otherwise stated.on the parallel processing of hundreds of thousands (if not
hundreds of millions) of physically sequestered, indivi-
dually (clonally) amplified copies of DNA, allowing for the
generation of massive amounts of data in an extremely
short period of time. The resulting datasets, which have
become rich gold mines for researchers, provide catalogs of
single nucleotide polymorphisms (SNPs), deletion/insertion
polymorphisms, copy number variants, and translocations.
NGS DNA methodologies allow researchers to capture
particular regions of interest contained within a genome or
sequence the entire genome as a whole (whole-genome
sequencing). Enriched regions may be specific loci or small
genomic regions (targeted sequencing) or the sequences
of all known genes and functional elements (exome
sequencing). With each method having its own pros and
cons, one must consider the scientific objective along with
both cost and efficiency when choosing a method. One
should not require, for example, the entirety of an exome
to be sequenced if the functional variant in question is
suspected to be in a non-coding region or previously
implicated haplotype block. Similarly, the entire genome
need not be sequenced if the study design is focusing only
on variants affecting protein-coding genes. Finally, the
amount of sequence generated per sample must be taken
into account. NGS sequencers are currently optimized to
output a set number of reads per run, generally far in
searchers combine or ‘multiplex’ samples into shared lanes
to reduce cost. This can, however, lead to a decrease in
the overall number of reads per sample if the allocation is
not meted out judiciously and result in reduced reliability
of the calls due to insufficient coverage. Conversely, an
overabundance of reads per sample may saturate coverage,
diminishing returns on variant calling. Numbers of reads
for a given sequence methodology have been empirically
ascertained, beyond which increased sequence data yield
little or no further variant information [1]. This may in-
crease costs unnecessarily, resulting in fewer samples run
for a given budget.td. The licensee has exclusive rights to distribute this article, in any medium, for
ime, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Wiley et al. Arthritis Research & Therapy 2014, 6:490 Page 2 of 8
http://arthritis-research.com/content/6/6/490The major NGS platforms currently available to re-
searchers and clinicians include Illumina’s HiSeq and
MiSeq, Life Technologies’ Ion Torrent and SOLiD, and
Roche’s 454. While the technologies empowering each of
these platforms are quite different, with each having its
own nuances in performance and powers of detection,
they all rely on the ability to shear DNA into short (<1 kb)
fragments, ligate adapters of known sequence to each end,
and then immobilize and clonally amplify these molecules
onto a solid substrate prior to undergoing massively paral-
lel sequencing. An in-depth discussion of the pros and
cons of each technology is beyond the scope of this re-
view, but they are reviewed in other publications [2-4].
Today, these methodologies have revolutionized disease-
gene discovery and are now being applied to genetics
studies of rheumatic disease. While candidate gene and
genome-wide association studies (GWASs) have had great
success in identifying candidate genes for many of the
rheumatic diseases (for example, >40 known genes in sys-
temic lupus erythematosus (SLE) [5], >100 in rheumatoid
arthritis (RA) [6], and >150 in inflammatory bowel disease
(IBD) [7]), the extent of heritability explained by theFigure 1 A comparison of two popular sequence enrichment method
interest are used to amplify the target area. (B) These PCR products are the
molecules (adapters). (C) Molecules are then ready for sequencing. (D) For
fragments which are subsequently ligated to sequencer-specific adapter DN
be complementary to the region of interest are incubated with the previou
region of interest are pulled down using streptavidin-coated magnetic beamajority of these genes remains small. DNA sequencing
methodologies will surely result in additional gene identi-
fications (especially rare variants that are not captured by
GWAS methods) that may help explain missing heritabil-




Targeted sequencing involves the enrichment of a certain
locus or group of loci in a varying number of samples.
The two most commonly used targeted sequencing ap-
proaches are based on either capture with complementary
oligomers (hybridization) or amplification via PCR (am-
plicon) (Figure 1). Hybridization utilizes short biotinylated
oligomers that have been designed, generally by an algo-
rithm supplied by the reagent manufacturer, to tile over
the locus/loci of interest. These ‘bait’ oligomers are hy-
bridized to the genomic DNA sample and allow for the
capture of their specific complementary DNA sequences.
This approach is generally favored for large numbers of
loci and has the ability to cover up to 20 million base pairss. (A) For amplicon enrichment, PCR primers specific to the region of
n prepared for sequencing via ligation with sequencer-specific DNA
hybridization enrichment, the entire genome is sheared into small
A molecules. (E) Biotinylated oligomers that have been designed to
sly generated sequencing library. (F) Captured molecules from the
ds. DNA molecules are then eluted and ready for sequencing (C).
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consist of primer-walking across the locus/loci of interest,
followed by pooling the sometimes large number of PCR
reactions prior to sequencing. This approach is primarily
for regions up to 1 to 2 Mbp total, but allows for large
numbers of samples to be pooled together in a single se-
quencing reaction. Targeted sequencing is often the method
of choice for follow-up studies of GWAS associations. Its
main disadvantage is that it is generally unable to perform
well across repetitive elements within the genome, regions
that have low-complexity, or extreme A-T or G-C sequence
content.
Exome sequencing is, for all intents and purposes, the
same as hybridization targeted capture in methodology.
The differences lie in the fact that the exome capture
systems have been specifically designed to only capture
the coding regions of known genes and, in some cases,
known functional non-coding elements of the genome.
This optimization allows for a single exome capture sys-
tem to enrich for 35 to 80 Mbp total. The goal in studying
the exomes is to identify mutations that alter the amino
acid content of a protein, possibly resulting in altered pro-
tein function. Exome capture systems may also include
the untranslated regions of genes, pseudogenes, long
non-coding RNAs, microRNA genes, and other genomic
elements of interest that do not necessarily fall under the
moniker of ‘gene’. The inclusion of these other loci is
heavily dependent on the manufacturer and version of the
exome capture system. Since it uses the same methods
as targeted sequencing, exome capture technology also
shares its disadvantages, with approximately 10% of the
exome routinely failing to be captured and, thus, being
unable to be sequenced.
Whole-genome sequencing allows for the potential
identification of every variant in the genome. It is the
most straightforward of the NGS methodologies since
the entire genome is prepared and placed onto the
sequencer with minimal processing. However, due to the
large number of sequencing reads necessary to cover the
entire genome, let alone the appropriate amount of
coverage necessary to generate good quality variant calls,
it remains the most expensive. For this reason very few
rheumatic disease studies have yet undertaken whole-
genome sequencing. However, we anticipate that this
will not be the case for much longer since the cost for
whole-genome sequencing continues to decrease.
While we provide below a few examples of how each
DNA sequencing methodology has been applied to vari-
ous rheumatic diseases, additional examples are included
for the reader in Table 1.
Other sequencing methodologies
While not a main focus of this review, there are other high-
throughput sequencing methods available to researchersthat focus on non-genetic variation (epigenetics and tran-
scriptomics). The epigenome consists of alterations result-
ing from environmental exposures to chemical, nutritional
and physical factors that ultimately result in changes
to gene expression, suppression, development, or tissue
differentiation without altering the underlying DNA se-
quence. Epigenetic modifications can occur on DNA
(methylation) or the histone proteins that compact DNA
into nucleosomes (histone modification). Several rheum-
atic disease studies are already utilizing powerful methods
to determine epigenetic influences on phenotype and are
discussed in multiple reviews [32-35].
Deep sequencing for transcriptomic studies (RNA-seq)
generates more detailed data, including specific isoform,
exon-specific transcript and allelic expression levels [36-38],
mapping of transcription start sites, identification of sense
and antisense transcripts, detection of alternative splicing
events, and discovery of unannotated exons [39,40]. To
date, RNA-seq methods have been conducted in rheum-
atic disease studies of RA [41] and SLE [42,43], and in a
murine model of inflammatory arthritis [44].
Targeted DNA sequencing approach in rheumatic
disease
A number of targeted deep sequencing studies for rheum-
atic diseases have been used to follow up associations
identified by GWASs or custom designed genotyping
arrays (Table 1) [25-28]. Adrianto and colleagues [27,28]
have performed two such studies in SLE-associated risk
loci, TNFAIP3 and TNIP1. TNFAIP3 was first identified as
an SLE risk gene by GWAS and encodes the ubiquitin-
modifying enzyme A20, which is a key regulator of NF-kB
activity [45,46]. After confirming genetic association in a
large case–control association study of five racially diverse
populations, Adrianto and colleagues utilized a targeted
sequencing approach of the associated TNFAIP3 risk
haplotype in seven carriers (two homozygotes and five
heterozygotes) [28]. Though they did not identify any
novel SNPs, they did identify a previously unreported sin-
gle base deletion present on all risk chromosomes. This
deletion was adjacent to a rare SNP found in Europeans
and Asians and, together, this SNP-indel variant pair
formed a TT >A polymorphic dinucleotide that bound to
NF-kB subunits with reduced avidity. In addition, the risk
haplotype that carried the TT >A variant reduced TNFAIP3
mRNA and A20 protein expression. TNIP1 (TNFAIP3 in-
teracting protein 1) has also been associated with SLE in
multiple studies, and in conjunction with their studies of
TNFAIP3, Adrianto and colleagues [27] performed a similar
targeted sequencing study of TNIP1. Targeted resequencing
data resulted in 30 novel variants that were then imputed
back into a large, ethnically diverse case–control study, and
conditional analysis was used to identify two independent
risk haplotypes within TNIP1 that decrease expression of
Table 1 Rheumatic disease studies utilizing next-generation DNA sequencing methodologies
Disease Sequencing
application
Platform Study design Sample size sequenced Population Associated genes Reference
AS Targeted Illumina Case–control 50 cases and 50 controls;





BD Exome Illumina Case–control 766 cases, 768 controls Japanese; Turkish IL23R, TLR4, MEFV [9]
















Family 1 case; 27 cases Caucasian PLCG2 [13]
DDH Whole exome Illumina Family 4 cases Caucasian CX3CR1 [14]




Gout Whole genome Illumina Case–control 457 cases Caucasian ALDH16A1 [16]
HUVS Whole exome/
targeted exome





Case–control 992 cases, 944 controls Caucasian GDF5 [18,19]





Case–control 34 cases, 74 controls Alaska Native MHC [21]
Exome Illumina Case–control 500 cases, 650 controls Caucasian CD2, IL2RA, IL2RB [22]





4 cases; 1,088 cases,
1,088 controls
Caucasian PLB1 [24]
SLE Targeted Illumina Case–control 74 cases, 100 controls Caucasian UBE2L3 [25]
Targeted Illumina Case–control 100 cases, 100 controls Caucasian IKBKE, IFIH1 [26]




Targeted Illumina Case–control 7 cases Caucasian TNFAIP3 [28]





Family 1 case; 3 cases, 3
unaffecteds
Caucasian PRKCD [30]
pSS Targeted Sanger Case–control 19 cases Caucasian TNFAIP3 [31]
AS, ankylosing spondylitis; BD, Behçet’s disease; IBD, inflammatory bowel disease; CU, cold-induced urticaria; DDH, developmental dysplasia of the hip; FMS, fibromyalgia
syndrome; HUVS, hypocomplementemic urticarial vasculitis syndrome; OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; pSS, primary
Sjögren’s syndrome.
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Wang and colleagues [25] conducted a targeted sequencing
study of the SLE-associated UBE2L3 locus in 74 SLE cases
and 100 European controls. They identified five novel vari-
ants (three SNPs and two indels) that were not present in
NCBI dbSNP build 132, one of which was strongly asso-
ciated with SLE (P = 2.56 × 10−6). The variants were thenimputed back into a large case–control dataset, which
ultimately led to the identification of a 67 kb UBE2L3 risk
haplotype in four racial populations that modulates both
UBE2L3 and UBCH7 expression.
C Wang and colleagues [26] explored the variants
within and around IKBKE and IFIH1, genes also previ-
ously identified as associated with SLE. These two genes
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strategy of exonic, intronic, and untranslated regions in
100 Swedish SLE cases and 100 Swedish controls. In
the course of their sequencing, they identified 91 high-
quality SNPs in IFIH1 and 138 SNPs in IKBKE, with 30%
of the SNPs identified being novel. Putative functional
alleles were then genotyped in a large Swedish cohort,
which ultimately yielded two independent association sig-
nals within both IKBKE (one of which impairs the binding
motif of SF1, thus influencing its transcriptional regulatory
function) and IFIH1.
Davidson and colleagues [8] utilized targeted sequen-
cing of the IL23R gene to identify rare polymorphisms
associated with ankylosing spondylitis in a Han Chinese
population. Targeted sequencing of a 170 kb region con-
taining IL23R and its flanking regions was performed in
100 Han Chinese subjects and again in 1,950 subjects of
European descent and identified several potentially func-
tional rare variants, including a non-synonymous risk
variant (G149R) that proved to be associated with the
disease.
Exome studies in rheumatic disease
Many studies have resequenced the exomes of candidate
genes to identify variants that are likely to influence pro-
tein function and, thus, have biological relevance (Table 1)
[9-11,22,29]. For example, Rivas and colleagues [11] uti-
lized targeted exome resequencing to query 56 loci previ-
ously associated with IBD. They used an amplicon pooling
strategy in 350 IBD cases and 350 controls and identified
429 high confidence variants, 55% of which were not in-
cluded in dbSNP. Seventy rare and low-frequency protein-
altering variants were then genotyped in nine independent
case–control datasets comprising 16,054 Crohn’s cases,
12,153 ulcerative colitis cases, and 17,575 controls, which
identified previously unknown associated IBD risk variants
in NOD2, IL18RAP, CUL2, C1orf106, PTPN22, and
MUC19. They also identified protective variants within
IL23R and CARD9. Their results were among the first
to support the growing hypothesis that common, low-
penetrance alleles as well as rare, highly penetrant
alleles can exist within the same gene. Other studies have
taken a whole exome sequencing approach to target
and evaluate all known exonic regions throughout the
genome [23].
A primary benefit of these DNA methodologies is the
ability to capture rare and low frequency variants that,
until now, were unknown. With low frequency variants,
however, the power of the widely used indirect linkage
disequilibrium-mapping approach is low. Therefore, sev-
eral studies have performed large-scale targeted exome
sequencing studies using genetic burden testing, a method
that evaluates the combined effect of an accumulation
of rare and low-frequency variants within a particulargenomic segment such as a gene or exon. Diogo and
colleagues [22] applied this strategy to the exons of 25 RA
genes discovered by GWAS while utilizing four burden
methods and identified a total of 281 variants (83% with
minor allele frequency <1% and 65% previously unde-
scribed), with an accumulation of rare nonsynonymous
variants located within the IL2RA and IL2RB genes that
segregated only in the RA cases. Eleven RA case–control
dense genotyping array datasets (ImmunoChip and GWAS)
comprising 10,609 cases and 35,605 controls were then
scrutinized for common SNPs that were in linkage
disequilibrium with the 281 variants identified by the
exome sequencing. Sixteen of 47 identified variants
were subsequently associated with RA, demonstrating
that, in addition to previously known common variants,
rare and low-frequency variants within the protein-coding
sequence of genes discovered by GWASs have small to
moderate effect sizes and participate in the genetic contri-
bution to RA. Kirino and colleagues [9] also utilized bur-
den testing while studying the exons of 10 genes identified
through GWAS that were associated with Behçet’s disease
and 11 known innate immunity genes in Japanese and
Turkish populations. They used three different burden
tests and were able to identify a statistically significant
burden of rare, non-synonymous protective variants in
IL23R (G149R and R381Q) and TLR4 (D299G and T399I)
in both populations, and association of a single risk vari-
ant inMEFV (M694V) within the Turkish population.
Whole-genome sequencing in rheumatic disease
Until only recently, whole-genome sequencing was an
unrealistic option for most studies due to its high costs.
Today, however, with a cost approaching $1,000 per sam-
ple [47], genetics and genomics researchers are finally able
to see this method as a valid option for their studies. To
date, few published large-scale whole-genome sequencing
studies have been conducted on a rheumatic disease.
Sulem and colleagues [16] carried out the first such study,
sequencing 457 Icelanders with various neoplastic, car-
diovascular and psychiatric conditions to an average depth
of at least 10× and identified approximately 16 million
variants. These variants were then imputed into a chip-
genotyped dataset of 958 gout cases and >40,000 controls
with more than 15,000 of these subjects also having mea-
sured serum uric acid levels. When analyzing gout as the
phenotype, two loci reached genome-wide significance:
a novel association with an exonic SNP in ALDH16A1
(P = 1.4 × 10−16), and a Q141K variant within ABCG2
(P = 2.82 × 10−12), a gene previously reported to be
associated with gout and serum uric acid levels. The
ALDH16A1 SNP displayed stronger association with gout
in males and was correlated with a younger age at onset.
Four loci reached genome-wide significant association
when evaluating association with serum uric acid levels:
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10−21), a novel association with the chromosome 1
centromere (P = 4.5 × 10−16), as well as previously re-
ported signals at SLE2A9 (P = 1.0 × 10−80) and ABCG2
(P = 2.3 × 10−20). Another study, by Styrkarsdottir and
colleagues [20], utilized whole-genome sequencing of an
Icelandic population to further inform a GWAS investi-
gating severe osteoarthritis of the hand. In this case, the
imputation of 34.2 million SNPs identified via whole-
genome sequencing of 2,230 Icelandic subjects into a
previously performed GWAS of 632 cases and 69,153
controls allowed the researchers to identify association
with 55 common (41 to 52%) variants within a linkage
disequilibrium block containing the gene ALDH1A2 and
four rare (0.02%) variants at 1p31. Other rheumatic dis-
ease studies have conducted much smaller scale whole-
genome sequencing in one to five individuals followed
by targeted exome or Sanger sequencing of the identi-
fied variants in larger samples [13].
DNA sequencing in families with rheumatic disease
For rheumatic diseases showing an autosomal dominant
or Mendelian inheritance pattern, the study of each gen-
ome across multiple generations of the same family can
shed light on the variant(s) or gene(s) responsible for
disease. Therefore, high-throughput DNA sequencing
studies are not limited just to disease cases and popula-
tion controls, but have been applied to family studies as
well [13,14,17,24]. Okada and colleagues [24] recently
applied whole-exome sequencing to a four-generation
consanguineous Middle Eastern pedigree in which 8 of
49 individuals (16.3%) were affected with RA, which was
much higher than the prevalence of RA in the general
Middle Eastern population (1%). By applying a novel
non-parametric linkage analysis method to GWAS data
that looked for regional IBD stretches with a loss of
homozygous genotypes in affected cases, they identified
a 2.4 Mb region on 2p23 that was enriched in the RA
cases. Whole-exome sequencing of 2p23 was performed
in four RA cases, which identified a novel single missense
mutation within the PLB1 gene (c.2263G >C; G755R).
Variants near the PBL1 gene were then evaluated in 11
GWAS datasets of 8,875 seropositive RA cases and 29,367
controls, which identified two independent intronic muta-
tions that, when evaluated as a haplotype, demonstrated
significant association with RA risk (P = 3.2 × 10−6). Fi-
nally, deep exon sequencing of PBL1 was performed in
1,088 European RA cases and 1,088 European controls,
and burden testing revealed an enrichment of rare vari-
ants within the protein-coding region of PBL1. Taken
together, these results suggest both coding and non-
coding variants of PBL1, a gene that encodes both pho-
pholipase A1 and A2 enzymatic activities, contribute to
RA risk.A major benefit of utilizing NGS methods within fam-
ilies is that researchers are now able to combine previ-
ously generated linkage information with new sequence
data to identify rare causal variants that contribute to
previously detected linkage signals.
Ombrello and colleagues [13] integrated NGS data
with previously generated linkage data in three families
with a dominantly inherited complex of cold-induced
urticaria, antibody deficiency, and autoimmunity. Previous
linkage analysis identified a 7.7 Mb interval on chromo-
some 16q21. Whole-genome sequencing of one affected
individual from the first family did not identify any novel
mutations within the linkage peak. When analyzing a
second family, however, a segregated haplotype containing
24 genes overlapped a linkage interval, and PLCG2 was
subsequently chosen as the most likely candidate. Sequen-
cing of PLCG2 within family 1 identified a 5.9 kb deletion
of exon 19 that was present only in the affected individ-
uals. A post hoc analysis of the whole genome data from
the family 1 individual confirmed the presence of this
deletion. Subsequent sequencing of this gene in the other
two families identified further deletions: transcripts in
family 2 that lacked exons 20 to 22 because of an 8.2 kb
deletion, and deletion of exon 19 in family 3 because
of a 4.8 kb deletion. Each of the three deletions af-
fected the carboxy-terminal Src-homology 2 (cSH2) do-
main of PLCG2, a domain that, in healthy individuals,
couples the enzymatic activity of PLCG2 to upstream
pathways. In these individuals, however, the deletions re-
sulted in auto-inhibition and constitutive phospholipase
activity.
Sanger sequencing in rheumatic disease
Until the application of NGS, Sanger sequencing, which
was developed in 1977, was the most widely used se-
quencing method. However, the advent of NGS does not
necessarily ring the death-knell for Sanger sequencing
for one or a handful of variants. While on the wane as a
large-scale experimental technique, this tried and true
methodology still retains usefulness and economy in
large-scale replication and screening assays. Many still
consider this method to be the ‘gold standard’ and will
utilize Sanger sequencing to validate the results generated
by their high-throughput sequencing methods [20,23,24,30].
In addition, recently published studies have applied no
other method but Sanger sequencing for deep se-
quencing of extremely specific regions in smaller numbers
of samples. These include a search for rare variants
across GDF5, a gene harboring a known susceptibility
variant for osteoarthritis in 992 cases and 944 con-
trols [18,19], a similar rare variant screen focused on
TNFRSF6B in pediatric-onset IBD [12], exome sequen-
cing of TNFAIP3 in 19 primary Sjögren’s syndrome pa-
tients with lymphoma [31], and targeted sequencing of the
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trols [29].The future of sequencing
While a tried and true advancement in the genetics and
genomics of rheumatic disease studies, deep sequencing,
as a technological field, has and will continue to remain in
a state of flux. With the continued refinement of technol-
ogy and methods, sequencing costs have dropped tremen-
dously over the past 5 years and, as of the drafting of this
manuscript, whole-genome sequencing of humans has
dropped to less than $1,000 per sample [48]. At this price
point, the continued viability of exome sequencing as a
widespread technique has yet to be determined. Indeed, it
is quite within the realm of possibility that all patients will
have their genomes sequenced as a routine test at presen-
tation to their healthcare provider. The foreseeable rise of
nanopore sequencers and other ‘third-generation’ sequen-
cers able to process single molecules of DNA may make
bedside sequencing a reality.Note: This article is part of the series ‘New technologies’. Other
articles in this series can be found at http://arthritis-research.
com/series/technology.Abbreviations
GWAS: Genome-wide association study; IBD: Inflammatory bowel disease;
Mbp: Million base pairs; NGS: Next-generation sequencing; PCR: Polymerase
chain reaction; RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus;
SNP: Single nucleotide polymorphism.
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